The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients

被引:40
作者
Hajer, Gideon R. [1 ]
Dallinga-Thie, Geesje M. [2 ]
van Vark-van der Zee, Leonie C. [3 ]
Visseren, Frank L. J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[2] Amsterdam Med Ctr, Dept Vasc Med, Lab Expt Vasc Med, Amsterdam, Netherlands
[3] Erasmus MC, Lab Vasc Med, Rotterdam, Netherlands
关键词
Simvastatin; Ezetimibe; Postprandial lipid levels; Lipoprotein composition; Metabolic syndrome; Crossover design; TRIGLYCERIDE TRANSFER PROTEIN; HIGH-DOSE SIMVASTATIN; NONFASTING TRIGLYCERIDES; PLASMA-LIPOPROTEINS; ATORVASTATIN; CHOLESTEROL; ABSORPTION; PARTICLES; SECRETION; LIPASE;
D O I
10.1016/j.atherosclerosis.2008.04.035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Fasting and postprandial hypertriglyceridemia are essential features of metabolic syndrome. Statins decrease fasting lipid levels but fail to reduce fat load induced hypertriglyceridemia. We established whether ezetimibe combined with simvastatin differently influences post fat load lipid levels and lipoprotein composition its compared to simvastatin 80 mg monotherapy in obese male metabolic syndrome patients. Methods: Prospective. randomized. double blind. crossover trial. Male obese metabolic syndrome (ATPIII) patients (n = 19) were treated with simvastatin 80 mg and simvastatin/ezetimibe 10 mg/10 mg for 6 weeks. At the start of the Study and after each treatment period oral fat loading, tests were performed. Lipoprotein fractions (triglyceride-rich lipoproteins (TRL), IDL, LDL, and HDL) were isolated by density gradient ultracentrifugation. Postprandial changes in lipid levels were integrated as areas under the curve (AUCs). Results: Fasting LDL-C RLP-C and triglycerides were lowered equally by both simvastatin 80 mg and simvastatin/ezetimibe 10 mg/10 mg Also postprandial plasma triglyceride levels (net AUC-TG) were equally lowered after both treatments (5.16 +/- 0.50 mmol h/l after simvastatin/ezetimibe 10 mg/10 mg and 6.09 +/- 0.71 mmol h/l after simvastatin 80 mg) compared to fat loading Without treatment (6.64 +/- 0.86 mmol h/l). In addition. triglyceride-content in lipoprotein fractions after fat load (net AUCs) were also equally reduced after both treatments. Similarly, TRL. IDL and LDL cholesterol and apoB concentrations were equally affected by both treatment regimens. leading to a reduced number of circulating particles, in both conditions. However the composition of these particles remained the same. Conclusion: Simvastatin 80 mg and simvastatin/ezetimibe 10 mg/10 mg were equally effective in reducing fasting and post fat load plasma lipid, and lipoprotein concentrations and lipoprotein composition in obese metabolic syndrome patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:216 / 224
页数:9
相关论文
共 30 条
  • [1] Overproduction of large VLDL particles is driven by increased liver fat content in man
    Adiels, M
    Taskinen, MR
    Packard, C
    Caslake, MJ
    Soro-Paavonen, A
    Westerbacka, J
    Vehkavaara, S
    Hakkinen, A
    Olofsson, SO
    Yki-Jarvinen, H
    Borén, J
    [J]. DIABETOLOGIA, 2006, 49 (04) : 755 - 765
  • [2] The metabolic syndrome - a new worldwide definition
    Alberti, KGMM
    Zimmet, P
    Shaw, J
    [J]. LANCET, 2005, 366 (9491) : 1059 - 1062
  • [3] Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
    Bansal, Sandeep
    Buring, Julie E.
    Rifai, Nader
    Mora, Samia
    Sacks, Frank M.
    Ridker, Paul M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (03): : 309 - 316
  • [4] Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system
    Bjornheden, T
    Babyi, A
    Bondjers, G
    Wiklund, O
    [J]. ATHEROSCLEROSIS, 1996, 123 (1-2) : 43 - 56
  • [5] Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia
    Boquist, S
    Karpe, F
    Danell-Toverud, K
    Hamsten, A
    [J]. ATHEROSCLEROSIS, 2002, 162 (01) : 163 - 170
  • [6] Chapman MJ, 1998, EUR HEART J, V19, pA24
  • [7] Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containg lipoprotein and HDL in type 2 diabetes - A potential mechanism to lower plasma triglycerides
    Dallinga-Thie, GM
    Berk-Planken, IIL
    Bootsma, AH
    Jansen, H
    [J]. DIABETES CARE, 2004, 27 (06) : 1358 - 1364
  • [8] Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
    Davidson, MH
    Ballantyne, CM
    Kerzner, B
    Melani, L
    Sager, PT
    Lipka, L
    Strony, J
    Suresh, R
    Veltri, E
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (08) : 746 - 755
  • [9] Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
    Davidson, MH
    McGarry, T
    Bettis, R
    Melani, L
    Lipka, LJ
    LeBeaut, AP
    Suresh, R
    Sun, S
    Veltri, EP
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) : 2125 - 2134
  • [10] Effects of rosuvastatin, atorvastatin, simvastatin, and prarvastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
    Deedwania, PC
    Hunninghake, DB
    Bays, HE
    Jones, PH
    Cain, VA
    Blasetto, JW
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (03) : 360 - 366